Novartis and Bristol Myers Squibb (BMS) have both paused clinical trials of CAR-T cell therapies for lupus and other autoimmune diseases due to concerning safety findings. 

Novartis has placed holds on trials of rapcabtagene autoleucel (rap-cel), stopping screening, randomisation, and treatment administration in trials in lupus, myasthenia gravis, multiple sclerosis and other autoimmune conditions. 

The decision was made after three study participants experienced a rare, potentially life-threatening inflammatory reaction known as immune effector cell-associated hemophagocytic syndrome (IEC-HS) and later died from complications.  

Meanwhile, BMS also paused enrolment in Phase II trials of zolacabtagene autoleucel (zola-cell or BMS-986353) in autoimmune diseases after observing what the company described as “transient and reversible inflammatory events”. 

Novartis said it is reviewing the clinical and safety data with regulators, while Bristol Myers Squibb said the voluntary pause is a precaution while it reviews data across the programme. 

In a Phase I trial of zola-cel, 71 patients were treated across the systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and idiopathic inflammatory myopathies (IIM) cohorts. The preliminary safety and efficacy results showed robust CAR-T cell expansion, complete B cell depletion and re-emergence of a naive B cell phenotype across all three cohorts.   

BMS stated at the time that all cohorts presented an acceptable safety profile, with the majority of adverse events occurring shortly after infusion and resolving quickly with standard management protocols.